Innovative Medicine

• Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis or death • Data selected to open the plenary presentation at ASCO 2026 and published in The New England Journal of Medicine

• More than one-third of responders with previously treated disease achieved complete responses, with median duration of response not yet reached, as reported in new Journal of Clinical Oncology publication • RYBREVANT FASPRO™, an EGFR- and MET-targeting dual inhibitor, is the first and only subcutaneous therapy being evaluated in this setting • Johnson & Johnson submitted a supplemental Biologics License Application to U.S. FDA seeking approval for this indication

• Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson’s RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease • Consistent responses observed across atypical EGFR mutation subgroups, including those historically associated with poorer outcomes • ASCO 2026 results reinforce the significance of RYBREVANT®-based regimens for patients across EGFR mutations

• Building on the recent approval of TECVAYLI® plus DARZALEX FASPRO®, MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of TECVAYLI® as early as second line • TECVAYLI®delivered deep and durable responses, with nearly two-thirds of patients achieving a complete response or better

TREMFYA® showed significant inhibition of structural joint damage in adults with active psoriatic arthritis

• More than 90% of patients surveyed who underwent bladder removal or received BCG report negative impact on most aspects of their lives • Among patients treated with BCG, three-quarters describe managing the treatment-related physical symptoms as humiliating • Patients and urologists point to the importance of advancing treatments that may better reflect patient preferences and quality‑of‑life considerations

· Johnson & Johnson will present 30+ abstracts at European Hematology Association 2026, highlighting leadership in hematology with data across multiple myeloma and leukemia, and first pivotal data in warm autoimmune hemolytic anemia · Phase 3 results evaluate the potentially transformative investigational combination of TALVEY®, the first GPRC5D‑targeted bispecific antibody, in combination with DARZALEX FASPRO® with or without pomalidomide for patients with relapsed or refractory multiple myeloma in earlier lines of therapy · Pivotal Phase 2/3 results potentially position IMAAVY® as the first FDA-approved treatment for warm autoimmune hemolytic anemiaa designed to target the IgG autoantibodies responsible for red blood cell destruction

Oral presentations feature CAPLYTA® long-term data assessing relapse risk reduction in schizophrenia and new seltorexant analyses in major depressive disorder (MDD) with insomnia symptoms 18 abstracts highlight J&J’s leadership and deep portfolio in neuropsychiatry at the American Psychiatric Association (APA) and American Society of Clinical Psychopharmacology (ASCP) Annual Meetings

Generation Fine launches after global survey finds nearly 4 in 5 patients living with major depressive disorder don’t believe antidepressants will help them reach remission Campaign draws on expertise of Mental Health America and elevates the voices of leading mental health advocates, including Kyle Long, television studio analyst, retired National Football League (NFL) player